Research output per year
Research output per year
Personal profile
Biography
With more than a decade of experience in clinical trial management, Lucy Read has built her career around advancing impactful research in both UK and global health.
She has worked as a Clinical Trial Manager at the Global Health Trials Unit since 2020. During this time Lucy has overseen a diverse portfolio of studies focused on improving healthcare outcomes in resource-limited settings across sub-Saharan Africa and the Global South.
Her role spans the full trial lifecycle, from protocol development and regulatory approvals to recruitment, data management, adherence to ethical and regulatory standards and close out. She has expertise in project management, monitoring and oversight, data integrity, and cross-functional team leadership.
Lucy is passionate about using clinical research to address healthcare disparities and is committed to contributing to studies that have a tangible impact on global health. Her goal is to continue supporting high-quality, ethical research that improves patient outcomes, particularly in underserved communities.
Fingerprint
Dive into the research topics where Lucy Read is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands
Dickinson, L., Singh, Y., Semakula, J., Chodacki, P., Kassim, S., Namuddu, D., Sihlangu, M., Read, L., Else, L., Reynolds, H., Thompson, B., Monk, R., Lawson, A., Ayre, C., Read, J., Wang, D., Waitt, C., Orrell, C. & Khoo, S., 1 Sept 2025, In: British Journal of Clinical Pharmacology. 91, p. 11 1 p.Research output: Contribution to journal › Meeting Abstract
Open Access -
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., Read, L., Read, J., Stemmet, L. A., Mrubata, M., Byrne, K., Seden, K., Twimukye, A., Theunissen, H., Hodel, E. M., Chiong, J., Hu, N. C., Burger, D., Wang, D. & Byamugisha, J. & 30 others, , 1 Aug 2022, In: The Lancet HIV. 9, 8, p. e534-e543Research output: Contribution to journal › Article › peer-review
Open AccessFile42 Citations (Scopus) -
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial: a non-randomised, phase 2 trial
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., O'Brien, S. G., Read, L., Foroni, L. & Copland, M., 1 Jul 2019, In: The Lancet Haematology. 6, 7, p. e375-e383Research output: Contribution to journal › Article › peer-review
Open Access152 Citations (Scopus)